Surveillance Imaging Protocol for NHL Post-Treatment with Non-Avid Splenic Findings
For a patient with non-Hodgkin lymphoma who has completed systemic therapy and shows splenomegaly with small non-FDG-avid nodules on post-treatment PET/CT, perform surveillance CT scans no more than every 6 months for up to 2 years post-treatment completion, then no more than annually thereafter, with clinical follow-up every 3-6 months for 5 years. 1
Interpretation of Current Findings
Your patient's post-treatment PET/CT findings require careful interpretation:
- Splenic nodules <1.5 cm with FDG uptake lower than surrounding spleen are considered negative for lymphoma 2
- Splenomegaly alone without increased FDG avidity does not indicate active disease
- These findings are consistent with complete metabolic response despite residual anatomic abnormalities
Structured Surveillance Protocol
Years 0-2 Post-Treatment:
- CT surveillance: Every 6 months maximum 1
- Clinical visits: Every 3-6 months with history, physical exam, CBC, metabolic panel, and LDH 1, 3
- PET/CT: NOT recommended for routine surveillance 4, 3
Years 2-5 Post-Treatment:
- CT surveillance: No more than annually 1
- Clinical visits: Every 6 months 1
- Continue laboratory monitoring
Beyond 5 Years:
- Annual clinical follow-up or as clinically indicated 1
- No routine surveillance imaging unless clinically indicated 4, 3
Critical Evidence-Based Rationale
The recommendation against routine surveillance imaging is strongly supported:
- 77.9% of NHL relapses are detected by patient symptoms or physical examination findings, not surveillance imaging 5
- No overall survival difference exists between surveillance-detected versus symptom-detected relapses 5, 6
- False-positive rate with PET exceeds 20%, leading to unnecessary biopsies, anxiety, and costs 3
- Surveillance PET/CT accounts for >75% of follow-up healthcare costs in the first 2 years 5
When to Obtain Imaging Outside Protocol
Perform imaging immediately if any of the following develop:
- New or worsening B symptoms (fever, night sweats, weight loss)
- Rising LDH levels suggesting transformation 1
- Single site growing disproportionately 1
- New extranodal disease on physical examination
- Palpable lymphadenopathy on clinical exam
- Cytopenias not otherwise explained
Special Consideration for Transformation
If clinical suspicion for histologic transformation arises:
- FDG-PET may help identify areas suspicious for transformation 1
- Direct biopsy to the most FDG-avid area 1
- Functional imaging does NOT replace biopsy for diagnosis 1
Important Caveats
Residual masses on imaging: Even large residual masses without FDG avidity represent complete metabolic response and do not require additional treatment 4, 2. The size should be documented for future comparison 7.
Timing consideration: Your current post-treatment PET/CT should have been performed at least 3 weeks (preferably 6-8 weeks) after chemotherapy completion to minimize false-positive inflammatory changes 4, 2.
Indolent vs aggressive histology: While the general surveillance principles apply to most NHL subtypes, patients with residual intra-abdominal or retroperitoneal disease after treatment for indolent lymphomas may warrant more judicious use of surveillance CT 3, though this remains controversial 8.
What NOT to Do
- Do not perform routine surveillance PET/CT scans - they are costly, expose patients to radiation, have high false-positive rates, and do not improve survival 4, 3, 5
- Do not obtain imaging more frequently than recommended - 80% of relapses are identified clinically without imaging 4
- Do not make treatment decisions based solely on PET findings without histologic confirmation, especially for new lesions 4